Holen Sie sich die Stockscreener-App
0.00
100.00%
-12.00
Handel nachbörslich:
13.00
13.00
+
Schlusskurs vom Vortag:
$12.00
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$614.00K
Nettoeinkommen (Verlust:
$-76.35M
KGV:
0.00
EPS:
-47.63
Netto-Cashflow:
$-31.51M
1W Leistung:
-0.37%
1M Leistung:
-56.83%
6M Leistung:
-76.92%
1J Leistung:
+245.37%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$13.40
52-Wochen-Spanne:
$0.00
$13.40
Finch Therapeutics Group Inc Stock (FNCH) Company Profile
Firmenname
Finch Therapeutics Group Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie FNCH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FNCH
Finch Therapeutics Group Inc
|
0.00 | 0 | 614.00K | -76.35M | -31.51M | -47.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Finch Therapeutics Group Inc Stock (FNCH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | BofA Securities | Buy |
| 2021-04-13 | Eingeleitet | Evercore ISI | Outperform |
| 2021-04-13 | Eingeleitet | Jefferies | Buy |
Finch Therapeutics Group Inc Aktie (FNCH) Neueste Nachrichten
Financial Survey: Finch Therapeutics Group (NASDAQ:FNCH) and LadRx (OTCMKTS:CYTR) - Defense World
Microbiome Therapeutics Market Size, Growth, Trends & Forecast (2025–2035) - PharmiWeb.com
Microbiome Therapeutics Market: $2098.3 Mn by 2035 | 30.4% CAGR Growth Analysis - MarketReports.us
Autism Spectrum Disorder Pipeline Appears Robust With 18+ Key - openPR.com
Autism Spectrum Disorder Pipeline 2025: Therapies Under - openPR.com
Clostridium Difficile Infections Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Novartis, Astellas Pharma, Eli Lilly & Company AstraZeneca - Barchart.com
Autism Spectrum Disorder Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism Of Action, Route Of Administration, And Companies By Delveinsight - Menafn.com
5 Best Microbiome Companies (July 2025) - Securities.io
Autism Spectrum Disorder Clinical Trial Analysis: Key - GlobeNewswire
Live Biotherapeutic Products And Microbiome CDMO Market Size, Top Share to 2033 - Straits Research
Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 1.2% – Here’s Why - Defense World
Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities - GlobeNewswire
Clostridium Difficile Infections Pipeline 2025: MOA and ROA - openPR.com
Winchester Bancorp, Inc./MD/’s (NASDAQ:WSBK) Quiet Period Set To End on June 11th - Defense World
Reviewing Finch Therapeutics Group (NASDAQ:FNCH) and Mesoblast (NASDAQ:MESO) - Defense World
CBL International (NASDAQ:BANL) Initiates Share Buyback Plan - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) Trading Up 5.4% – Still a Buy? - Defense World
Ameriprise Financial Inc. Sells 3,274 Shares of iShares Agency Bond ETF (NYSEARCA:AGZ) - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Hydrofarm Holdings Group (NASDAQ:HYFM) Stock Price Up 8.2% – Here’s Why - Defense World
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $9.40 Consensus PT from Brokerages - Defense World
Bank of America Corp DE Has $10.76 Million Stock Holdings in Amer Sports, Inc. (NYSE:AS) - Defense World
Fecal Transplant Treatment Market: Manufacturer Capacity, Output, Sales, Competition Analysis Report 2025 - openPR.com
Live Biotherapeutic Product Market Growth Driven by Digestive - openPR.com
Price T Rowe Associates Inc. MD Purchases 6,966 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Head to Head Contrast: Crimson Wine Group (OTCMKTS:CWGL) versus Eastside Distilling (NASDAQ:BLNE) - Defense World
Life360 (NASDAQ:LIF) versus Workday (NASDAQ:WDAY) Head-To-Head Comparison - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) and Quince Therapeutics (NASDAQ:QNCX) Head to Head Comparison - Defense World
Clostridium Difficile Infections Clinical Trials 2025: EMA, - openPR.com
Kesmalea Therapeutics Appoints Industry Veteran Tim Clackson to Board of Directors - BioSpace
Stifel Financial Corp Acquires 1,495 Shares of Iridium Communications Inc. (NASDAQ:IRDM) - Defense World
Dimensional Fund Advisors LP Has $4.56 Million Position in Red River Bancshares, Inc. (NASDAQ:RRBI) - Defense World
Alvotech (ALVO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Microbiome Therapeutic Market Poised to Reach USD 3,121.8 Million by 2035, Growing at a CAGR of 14.2% - openPR.com
Raymond James Financial Inc. Acquires Shares of 6,760 Kodiak Gas Services, Inc. (NYSE:KGS) - Defense World
Dimensional Fund Advisors LP Has $10.38 Million Stock Position in Ero Copper Corp. (NYSE:ERO) - Defense World
StockNews.com Downgrades Myriad Genetics (NASDAQ:MYGN) to Hold - Defense World
Raymond James Financial Inc. Takes $554,000 Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
H-CYTE (OTCMKTS:HCYTD) Stock Price Down 49.5% – What’s Next? - Defense World
Calamos Long/Short Equity & Dynamic Income Term Trust (NASDAQ:CPZ) Short Interest Down 15.0% in April - Defense World
Clostridium Difficile Infections Pipeline and Clinical Trials - openPR.com
Arquitos Capital's Largest Holdings For Q1 2025 - Seeking Alpha
Arquitos Capital Management Q1 2025 Investor Letter - Seeking Alpha
Global Human Microbiome Market: Exploring Technological Innovations Fueling 31% CAGR Growth by 2030 - PharmiWeb.com
Prosperity Bancshares (PB) Expected to Announce Quarterly Earnings on Wednesday - American Banking and Market News
Vanguard Group Inc. Increases Stake in Westrock Coffee (NASDAQ:WEST) - Defense World
Financial Contrast: Kiromic BioPharma (NASDAQ:KRBP) and Finch Therapeutics Group (NASDAQ:FNCH) - Defense World
Clostridium Difficile Infections Pipeline 2025: MOA, ROA, - openPR.com
Rising Prevalence Of Gastrointestinal Disorders Growth In Fecal Microbiota Transplantation (FMT) Market: A ... - WhaTech
Procaps Group (NASDAQ:PROC) Stock Price Down 40.3% – Time to Sell? - Defense World
Finanzdaten der Finch Therapeutics Group Inc-Aktie (FNCH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
1.09%
Kapitalisierung:
|
Volumen (24h):